There is growing interest in autologous stem cell transplantation (ASCT) for elderly patients with acute myeloid leukemia (AML). While mortality and toxicity from ASCT have been reduced, relapse rate is still high. In a prospective study, we investigated the feasibility of a new conditioning regimen consisting of high-dose idarubicin plus busulfan in AML patients aged over 60 years undergoing ASCT. A total of 14 patients (median age: 64 years) received 2 days continuous infusion of idarubicin at 20 mg/m 2 /day, followed by 3 days of oral busulfan (4 mg/kg/day) as conditioning. No case of transplantrelated mortality occurred. The median number of days to neutrophil (40.5 Â 10 9 /l) and platelet (420 Â 10 9 /l) recovery was 11 and 12, respectively. Cardiac toxicity was absent, while 12 patients (86%) had grade 3-4 mucositis. After a median follow-up of 9 months from ASCT, nine of 14 patients are alive in continuous complete remission (CR), four have relapsed at 3, 6, 8 and 9 months, and one died in CR1 from gastric cancer. Our data demonstrate the feasibility of a conditioning regimen based on high-dose idarubicin plus busulfan in elderly AML patients. Results concerning reduction of relapse rate need confirmation in a larger series with longer follow-up. The prognosis of acute myeloid leukemia (AML) in older individuals is still poor, due to either lower complete remission (CR) rate or higher incidence of relapse as compared to young/adult patients. [1] [2] [3] [4] [5] In an attempt to reduce the relapse rate, there is a growing interest in autologous stem cell transplantation (ASCT) for elderly patients with AML.
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Here, we report results of a prospective study to evaluate a reduced schedule of IBu regimen, specifically designed for AML patients aged more than 60 years undergoing ASCT.
Material and methods
Between March 1999 and October 2003, after obtaining written informed consent, 14 patients aged over 60 years with AML underwent ASCT after conditioning with IBu regimen. Diagnosis was based on the FAB classification criteria using standard morphology and cytochemistry 14 and confirmed in all cases by immunophenotypic analysis as previously described. 15 Clinical and hematological characteristics of patients are summarized in Table 1 . There were nine males and five females with a median age of 64 years (range 61-74). A total of 12 patients (86%) were autografted in CR1, two in CR2 (14%) including one case of acute promyelocytic leukemia (APL). Nine patients had de novo AML, five had AML secondary to previously diagnosed myelodysplastic syndrome (MDS). A minimum of 20 evaluable metaphases were analyzed from bone marrow (BM) collected at diagnosis prior to any treatment and classified according to ISCN criteria. 16 Karyotypic analysis was successful in all cases: among patients autografted in CR1, nine had normal karyotype, three complex karyotype; for patients receiving ASCT in CR2, the patient with APL had t(15;17) as the sole cytogenetic abnormality, the other had 6p-. All transplants were performed in single or double conventional room using peripheral blood stem cells (PBSC) collected after consolidation treatment followed by G-CSF. Prophylaxis against infection consisted of oral ciprofloxacin, while neither antiviral nor antifungal prophylaxis was adopted. In all patients, left ventricular ejection fraction (LVEF) was evaluated before and after ASCT and all showed a value of 50% or more. Patients were considered in CR when BM blasts were less than 5% with normal blood count and differential, in absence of extramedullary leukemia. In 12 patients, induction treatment consisted of continuous sequential infusion of fludarabine and cytarabine (ARA-C) as previously reported. 17 Briefly, fludarabine was administered at a loading dose of 10 mg/m 2 over 15 min at day 0 followed by a CI of 20 mg/m 2 /24 h for 72 h. ARA-C was given at a loading dose of 390 mg/m 2 over 3.5 h after fludarabine and then as CI at 1440 mg/m 2 /24 h for a total of 96 h. G-CSF was added at day þ 15 at a dose of 5 mg/kg. Following CR, patients were given an additional course reduced by 1 day (CI fludarabine for a total of 48 h and CI ARA-C for a total of 72 h). G-CSF at 10 mg/kg was added at day þ 15 after consolidation in order to shorten neutropenia and mobilize hematopoietic precursors. Overall, mobilization of CD34 þ cells was attempted in 19 patients after consolidation with CI fludarabine and ARA-C and was successful in 13 (68%). Among these, 12 were actually autografted and are included in the present series, one experiencing early relapse. The AML patient autografted in CR2 had received IDA, ARA-C and etoposide as induction and consolidation and failed to mobilize stem cells. While waiting for a second consolidation, she relapsed; CR2 was achieved with the fludarabine þ ARA-C þ G-CSF (FLAG) regimen, 18 and successful collection of CD34 þ cells was obtained following an additional FLAG course while in CR2. The patient with APL, aged 69 years, had been given the AIDA protocol 19 and, after hematologic relapse, achieved CR2 with intermediate dose of ARA-C plus mitoxantrone. In this patient, PBSCs were collected after consolidation, following demonstration of sustained negativity for the PML/RARalpha fusion gene. 20 The median number of months between diagnosis or relapse and ASCT was 4 (range 2-5). The median number of CD34-positive cells infused was 5.5 Â 10 6 /kg (2.5-19). The reduced IBu conditioning consisted of high-dose IDA administered at 20 mg/m 2 /day as CI for 2 days (day -11 to day -10) followed by oral Bu given at 4 mg/kg/day from day -4 to day -2. To prevent seizures, phenytoin (100 mg) was given orally once daily beginning 24 h before the first dose of Bu and continued until 24 h after the last dose. All transfused blood products were depleted of leukocytes to minimize the risks of alloimmunization and graft-versushost disease. Toxicity was recorded prospectively according to WHO criteria. 21 Disease-free survival (DFS) was defined as the time from CR achievement to relapse or death from any cause, overall survival (OS) as the time from diagnosis until death from any cause. DFS and OS were calculated by Kaplan-Meier method. 22 
Results
All patients achieved engraftment with full hematopoietic recovery and no death from ASCT. The median number of days to stable recovery of neutrophils of 0.5 Â 10 9 /l and platelets of 20 Â 10 9 /l was 11 (9-19) and 12 (6-38), respectively. The median number of platelet and blood units transfused was 3 (1-7) and 4 (0-5), respectively. As shown in Table 2 , apart from one occurrence of grade 4 nausea and vomiting, the only episodes of WHO grade 3-4 extra-hematological toxicity consisted of stomatitis (grade 3 n ¼ 8, grade 4 n ¼ 4) that occurred in 12 patients (86%), and in all cases required total parenteral nutrition (TPN). Of Idarubicin and busulfan as conditioning for elderly AML F Ferrara et al note, narcotic analgesics were used only in three patients to treat pain due to severe mucositis. In the other patients, nonsteroid analgesic drugs were sufficient. In all patients, stomatitis resolved after hematopoietic recovery. Fever occurred in 13 patients; there were 10 episodes of fever of unknown origin (FUO) and three documented infections, two bacterial pneumonia and one pulmonary aspergillosis, which resolved with antibiotic and antifungal therapy after hematopoetic recovery. All febrile patients received empiric broad-spectrum antibiotic therapy, while liposomal amphotericin B was administered to five patients (one for documented aspergillosis and four as empiric treatment). Overall, no case of TRM occurred. Of note, LVEF examination post-ASCT did not reveal cardiac toxicity in any patient. After a median follow up of 9 months (range 1-49), nine patients (64%) are in continuous CR1, while four (29%) have relapsed at 3, 6, 8 and 9 months from ASCT, respectively; three have died from progressive disease, while one is alive and is receiving only support. Among relapsed patients, one had been autografted in CR2, and three had AML secondary to previously diagnosed myelodysplastic syndrome. One patient died from gastric cancer, while in sustained CR1. Median overall and DFS have not yet been reached after a median follow up of 9 months from transplantation and 14 months from diagnosis as shown in Figure 1 .
Discussion
Relapse rate higher than 50% are reported in elderly AML patients after ASCT. 10, 11 Different approaches including in vivo or ex vivo purging, immunotherapy post-ASCT and intensification of the conditioning regimen have been investigated in an attempt to achieve more durable disease control. [23] [24] [25] Although the adoption of alternative regimens such as BAVC result in lower TRM as compared to BuCy2, the relapse rate is higher. 13 More recently, promising results have been reported with reduced intensity allogeneic SCT, but toxicity is still relevant and a compatible donor is needed. 26 Preliminary data suggest that the addition of IDA may result in a reduction of relapse rate either in autologous or in allogeneic SCT. [27] [28] [29] In the present study, the choice of high-dose IDA given as continuous infusion was supported by previous data demonstrating a significant reduction in relapse rate for patients treated with IDABuCy or IDA-TBI-Cy when compared with historical controls conditioned with classical regimens including BuCy or TBI-Cy. 30 However, our regimen relies on the specific increase of the dose of IDA, which was given as CI for 48 h at 20 mg/m 2 /day in combination with oral Bu at 4 mg/kg for 3 days, as well as on the removal of cyclophosphamide. It is noteworthy that the BuCy and BuCy2 regimens were proposed for the allogeneic setting, the cyclophosphamide included for immunosuppression rather than as a specific antileukemic agent. In fact, cyclophosphamide is not included in most induction or consolidation regimens for AML and its removal is expected to significantly reduce the hematological and extra-hematological toxicity as well as post-transplant immunosuppression. On this basis, we treated 14 consecutive elderly AML patients with a median age of 64 years. All patients achieved full engraftment with fast hematopoietic recovery, and no TRM was observed. Severe mucositis requiring TPN was the most prominent toxic effect; therefore, new approaches including new agents and/or intravenous busulfan could be offered to IBu-treated patients to attenuate epithelial damage. Despite the high-dose IDA, no cardiotoxicity was recorded in any patient. However, it should be noted that most patients in this series did not receive any anthracycline therapy during induction or consolidation and this may have substantially accounted for the absence of cardiac toxicity. Of interest, no patient needed hospitalization in the post-ASCT period because of FUO or documented infection. Obviously, the use in all patients of PBSCs as well as the relatively high median number of CD34-positive cells infused may consistently shorten the duration of neutropenia and thrombocytopenia. Furthermore, whatever the age, AML patients receiving ASCT are highly selected for inclusion into clinical trials, CR achievement, successful mobilization and clinical eligibility to the procedure. 31 It is noteworthy that 68% of patients had successful mobilization of PBSCs after induction/consolidation treatment including fludarabine. Concern has been raised regarding the ability to mobilize sufficient PBPCs for autografting after purine analogues in AML 32 as well as in lymphoproliferative disorders. 33 However, after conventional FLAG therapy, we previously reported a mobilization rate comparable to that observed in this series in AML with trilinear dysplastic abnormalities; 18 in addition, we cannot exclude the possibility that fludarabine given as CI can result in less impairment of stem cell mobilization capacity.
In conclusion, despite the small number of patients studied, our results demonstrate the feasibility of high-dose IDA in association with Bu as a conditioning regimen in an elderly AML population with a median age of 64 years. While the relapse rate seems encouraging compared with previous series conditioned with alternative regimens, 6, 7, 13 Idarubicin and busulfan as conditioning for elderly AML F Ferrara et al longer follow-up is required to verify whether the IBu regimen is actually superior to the standard BuCy or other combinations. A randomized study would provide definitive information about the clinical efficacy of such an approach.
